The company beat analyst expectations for both revenues and adjusted earnings per share for the quarter.
The company said selling this business unit frees it to focus on developing new maternal and fetal health solutions for the US and elsewhere.
The company's fourth quarter revenues dropped by less than 1 percent compared to the same period last year, but missed analyst estimates.
The company has been quietly working on a fully automated NIPT for trisomies 21, 13, and 18 that requires neither next-gen sequencing nor microarray technology.
PerkinElmer bought the Swedish NIPT firm for an undisclosed amount to beef up its maternal fetal health portfolio.
The two companies are extending an existing agreement that provides for PerkinElmer to supply Agilent with chips for its 2100 Bioanalyzer system.
The investment bank also initiated coverage of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters with a Hold rating.
Agilent will pay Enzo $9 million to settle the suit, which involved a US patent issued to Enzo and describing non-porous solid supports for nucleic acids.
The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.
The company's Signals for Translational provides pharmaceutical and other researchers with tools for aggregating and analyzing various kinds of data including NGS.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.